A Phase 2, Interventional, Randomized, Double-Blind, Placebo-Controlled Pilot Study of Glucagon RTU in Subjects Who Experience Hyperinsulinemic Hypoglycemia After Bariatric Surgery
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- Sponsors Xerion Pharmaceuticals
- 07 Nov 2019 According to a Xeris Pharmaceuticals media release, data from the in-clinic portion of the study is expected before year end 2019.
- 27 Jun 2019 According to a Xeris Pharmaceuticals media release, the first subject from this study has been dosed.
- 05 Jun 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.